REGAL- Recurrent Glioblastoma Treated with Selinexor and Temozolomide: An Open-Label, Multicenter Phase 1 Study of Selinexor with Temozolomide in Patients with Recurrent Glioblastoma
Sponsor: |
Karyopharm, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR7797 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of the research study is to see if selinexor has any effects against your cancer and toevaluate the side-effects of selinexor or selinexor in combination with temozolomide (TMZ ). One specific way cancer cells continue to grow is by getting rid of certain proteins called tumor suppressor proteins that would normally cause cancer cells to die. This study drug, Selinexor, works by keeping tumor suppressing proteins within the nucleus of the cell, thus causing the cancer cells to die or stop growing.
This study is closed
Investigator
Andrew Lassman, MD
Are you 18 years of age or older? |
Yes |
No |
Have you been diagnosed with glioblastoma? |
Yes |
No |
Have you received first line treatment of radiation and temozlomide with or without surgery? |
Yes |
No |
Has your disease recurred following this initial treatment? |
Yes |
No |